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Background: We sought to compare the effectiveness and safety of low- and high-doses of aspirin in preventing adverse outcomes after 
percutaneous coronary intervention (PCI).
Methods: We studied 2820 consecutive patients who underwent coronary stenting for stable or unstable coronary artery disease (excluding 
cardiogenic shock) discharged alive without any complications between 2001 and 2007. Patients were categorized based on the discharge 
aspirin dose into low-dose (81 mg/day, n = 313) or high dose (162-325 mg/day, n = 2507) groups. The primary end-points (adjusted using Cox 
Proportional Hazard and propensity scores) were major adverse cardiovascular events [MACE= composite of death, myocardial infarction, stent 
thrombosis, or target vessel revascularization] and net adverse clinical events [NACE=composite of MACE and Thrombolysis in Myocardial Infarction 
TIMI (major or minor) bleeding] at 1 year.
Results: In the low-dose vs. high-dose groups, MACE occurred in 8.6 vs. 9.2% (log rank p = 0.71) and NACE in 11 vs. 10% (log rank p = 0.58). In 
multivariable analysis, low-dose aspirin was not associated with worse outcomes [adjusted HR (95% CI) 0.74 (0.49-1.14) for MACE; 1.03 (0.71-
1.50) for NACE].
Conclusions: Our data showed that in contemporary clinical practice, the use of low-dose aspirin was as effective and safe as high-dose aspirin in 
the post-PCI setting. 
